• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Endothelin Receptor Antagonists Plus Sodium-Glucose Cotransporter 2 Inhibitors: Poster Child for a New ERA of Combination Therapies?内皮素受体拮抗剂加钠-葡萄糖协同转运蛋白2抑制剂：联合治疗新时代的典型代表？
J Am Soc Nephrol. 2024 Oct 1;35(10):1306-1308. doi: 10.1681/ASN.0000000000000487. Epub 2024 Sep 4.
2
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.单独使用西他生坦和联合使用达格列净对慢性肾脏病患者液体潴留的影响。
J Am Soc Nephrol. 2024 Oct 1;35(10):1381-1390. doi: 10.1681/ASN.0000000000000436. Epub 2024 Jul 12.
3
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.2型糖尿病合并慢性肾脏病患者使用钠-葡萄糖协同转运蛋白2抑制剂与盐皮质激素受体拮抗剂联合治疗的心血管和肾脏结局：一项系统评价和网状Meta分析
Diabetes Res Clin Pract. 2022 Dec;194:110161. doi: 10.1016/j.diabres.2022.110161. Epub 2022 Nov 17.
4
Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?内皮靶向治疗：内皮素-1 拮抗剂与 SGLT-2 抑制剂联合应用：效果更佳？
Clin Sci (Lond). 2024 Jun 5;138(11):687-697. doi: 10.1042/CS20240605.
5
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.与单用达格列净相比，替勃龙坦与达格列净联合治疗对糖尿病和非糖尿病慢性肾脏病患者的影响。
Diabetes Obes Metab. 2025 Aug;27(8):4311-4319. doi: 10.1111/dom.16468. Epub 2025 May 21.
6
Upcoming drug targets for kidney protective effects in chronic kidney disease.慢性肾脏病中具有肾脏保护作用的潜在药物靶点。
Nephrol Dial Transplant. 2025 Feb 5;40(Supplement_1):i47-i58. doi: 10.1093/ndt/gfae216.
7
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.使用尿白蛋白肌酐比值（UACR）终点的非奈利酮与恩格列净联合治疗慢性肾脏病合并2型糖尿病患者的疗效（CONFIDENCE）试验：基线临床特征
Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022.
8
[Conservative Therapy in CKD: New Frontiers].[慢性肾脏病的保守治疗：新前沿]
G Ital Nefrol. 2024 Dec 23;41(6):2024-vol6. doi: 10.69097/41-06-2024-04.
9
Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.钠-葡萄糖共转运蛋白 2 抑制剂和非甾体类盐皮质激素受体拮抗剂：在肾素-血管紧张素系统阻断之外开创肾脏保护的新时代。
Nephrology (Carlton). 2021 Nov;26(11):858-871. doi: 10.1111/nep.13917. Epub 2021 Jul 6.
10
New pharmacological strategies for protecting kidney function in type 2 diabetes.新型药理学策略保护 2 型糖尿病患者的肾脏功能。
Lancet Diabetes Endocrinol. 2019 May;7(5):397-412. doi: 10.1016/S2213-8587(18)30263-8. Epub 2018 Dec 19.

本文引用的文献

1
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD.单独使用西他生坦和联合使用达格列净对慢性肾脏病患者液体潴留的影响。
J Am Soc Nephrol. 2024 Oct 1;35(10):1381-1390. doi: 10.1681/ASN.0000000000000436. Epub 2024 Jul 12.
2
Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease. sparsentan 在肾脏中的保护作用机制：慢性肾脏病模型研究中的经验教训。
Clin Sci (Lond). 2024 Jun 5;138(11):645-662. doi: 10.1042/CS20240249.
3
Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease.糖尿病和非糖尿病慢性肾脏病中的内皮素受体拮抗剂
Clin Kidney J. 2024 Mar 19;17(4):sfae072. doi: 10.1093/ckj/sfae072. eCollection 2024 Apr.
4
Combination therapy for kidney disease in people with diabetes mellitus.糖尿病患者肾病的联合治疗。
Nat Rev Nephrol. 2024 Jul;20(7):433-446. doi: 10.1038/s41581-024-00827-z. Epub 2024 Apr 3.
5
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.西他列汀联合达格列净对比达格列净治疗慢性肾脏病患者（ZENITH-CKD）：一项多中心、随机、阳性对照、2b 期临床试验。
Lancet. 2023 Nov 25;402(10416):2004-2017. doi: 10.1016/S0140-6736(23)02230-4. Epub 2023 Nov 3.
6
New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.SONAR的新见解表明，在内皮素受体拮抗剂中添加钠-葡萄糖协同转运蛋白2抑制剂可减轻液体潴留并增强蛋白尿减少效果。
Kidney Int. 2021 Feb;99(2):346-349. doi: 10.1016/j.kint.2020.09.026. Epub 2020 Nov 2.
7
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.阿曲生坦与伴有慢性肾脏疾病的 2 型糖尿病患者的肾脏事件（SONAR）：一项双盲、随机、安慰剂对照试验。
Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14.
8
Avosentan for overt diabetic nephropathy.阿伏生坦治疗显性糖尿病肾病。
J Am Soc Nephrol. 2010 Mar;21(3):527-35. doi: 10.1681/ASN.2009060593. Epub 2010 Feb 18.

Endothelin Receptor Antagonists Plus Sodium-Glucose Cotransporter 2 Inhibitors: Poster Child for a New ERA of Combination Therapies?

作者信息

Limonte Christine P, de Boer Ian H

机构信息

Division of Nephrology, Department of Medicine, University of Washington, Seattle, Washington; and Kidney Research Institute, University of Washington, Seattle, Washington.

出版信息

J Am Soc Nephrol. 2024 Oct 1;35(10):1306-1308. doi: 10.1681/ASN.0000000000000487. Epub 2024 Sep 4.

DOI:10.1681/ASN.0000000000000487
PMID:39230965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11452185/
Abstract
摘要